Drugs / NCR100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07139431 | Aug 2025 → Mar 2026 overdue | — | Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06049342 | Jan → Jun 2024 | osteoarthritis, knee | Nuwacell Biotechnologies Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06741098 | Feb 2025 → Nov 2026 expected | osteoarthritis, knee | Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCR100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06049342 ↗ |
| Modality | Cell therapy | “human induced pluripotent stem cell derived mesenchymal stromal cells (NCR100) injection” NCT06049342 ↗ |
| Route | Other | “one-dose intra-articular NCR100 injection” NCT06049342 ↗ |